U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07206225) titled 'A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer' on Sept. 25.
Brief Summary: The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab.
This study is for adults who have a type of bladder cancer that hasn't spread into the muscle layer of the bladder but is more likely to come back or grow. It includes people whose cancer has come back or hasn't gone away after receiving standard treatments like BCG. It may also include people who, based on their ...